Investor Relations

The genOway Share

Share Price

Stock Market : Alternext – Nyse Euronext

Ticker : ALGEN

Code ISIN : FR004053510

Number of outstanding shares : 5 983 466

First day of trading : May 7, 2007 Share –liquidity contracts

Shareholders

Dassault Développement: 19,76%
Finoway: 9,25%
Alexandre Fraichard: 8,59%
Others: 62,40%

Analyst Coverage
AlphaValue AlphaValue
Fabrice Farigoule (Lead analyst)
48 Bd des Batignolles
75017 Paris, France
Tel. : +33 1 70 61 10 50
Email : contact@alphavalue.eu
Click for the latest report:

alphavalue-genoway-report

Please note that any opinions, estimates or forecasts regarding genOway performance made by this analyst are his alone and do not represent opinions, forecasts or predictions by genOway or its management team.

genOway referencing of analyses provided by AlphaValue does not imply its endorsement of the information, conclusions or recommendations contained therein.

Requests for copies of analyst reports should be directly addressed to the above-mentioned analyst and institution.

Financial Calendar

2017 Annual revenues: January 23, 2018

Contacts

Investor relations
Please contact us at: finances@genoway.com

Financial Press Releases

14 September 2017: genOway: Financial results for the first half of 2017 (Only available in French)

11 July 2017genOway: 2017 Half-year revenues (Only available in French)

30 March 2017genOway: Financial results for 2016 (Only available in French)

16 January 2017genOway: 2016 Revenues (Only available in French)

19 December 2016: Two more contracts with TOP 20 pharmaceutical leaders signed; First objective of strategical plan reached (Only available in French)

12 September 2016: genOway: Financial results for the first half of 2016 (Only available in French)

12 July 2016genOway: 2016 Half-year revenues (Only available in French)

13 June 2016 genOway maintains its momentum with 2 new 3-year contracts signed with TOP 10 pharmaceutical leaders (Only available in French)

29 February 2016: genOway: Financial results for 2015 (Only available in French)

29 February 2016: genOway adds a new Worldwide Top 5 pharmaceutical leader to it’s clients portfolio; with a signed 5-years contract (Only available in French)

18 January 2016: Second contract with one of the Worldwide Top 5 pharmaceutical companies, aiming at an annual turnover of 1 Million USD (Only available in French)

08 December 2015: A new contract with a major biopharmaceutical company with a turnover of estimated one million euro per year during 3 years (Only available in French)

05 October 2015: Benjamin Bruneau est nommé Directeur Administratif et Financier de genOway (Only available in French)

01 October 2015: genOway: Financial results for the first half of 2015 (Only available in French)

16 Mars 2015: genOway: Financial results for 2014 (Only available in French)

15 Mars 2015: In 3 years from now to the worldwide leader for the development of genetically modified research models. (Only available in French)

17 October 2014: genOway: Financial results for the first half of 2014 (Only available in French)

06 October 2014: Christian Grenier is nominated Chairman of the Board of genOway (Only available in French)

23 July 2014: Over the last 18 months, pharmaceutical companies establishing corporate agreements to access genOway’s mouse model platform have doubled reaching 40% of the top 20 pharma

2 July 2014: genOway offers industry scientists immediate access to EUCOMM conditional KO mouse models

2 June 2014: New Accelerated Knockin / Humanization™ platform

28 May 2014: genOway signs new contracts in Israel and Gulf Arab States (Only available in French)

15 May 2014: genOway acquires exclusive sublicensing rights for the FLEx technology

03 Avril 2014: genOway: eligible for the new PEA-PME (Only available in French)

31 Mars 2014 : genOway: Financial results for 2013 (Only available in French)

30 Septembre 2013: genOway: Financial results for the first half of 2013 (Only available in French)

25 Mars 2013: genOway: Financial results for 2012 (Only available in French)

28 septembre 2012: genOway: Financial results for the first half of 2012 (Only available in French)

26 avril 2012: genOway signe un contrat cadre avec l'une des meilleures universités américaines (Only available in French)

30 mars 2012: genOway : Financial results for 2011 (Only available in French)

29 mars 2012: De la start up de l'ENS de Lyon à l'entreprise internationale. (Only available in french)

20 March 2012: StemCells, Inc. grants genOway exclusive license to gene insertion technology for genetically engineered mice

8 March 2012: genOway and PhenoPro, spin off of the Institut Clinique de la Souris, create the most advanced and innovative offer in animal model creation and phenotpying

23 January 2012: genOway renewals framework agreement with major european University (Only available in French)

19 December 2011: genOway consolidates its position in the United States with the signing of two framework contracts with prestigious American Universities (Only available in French)

20 October 2011: Ralph L. Brinster will be awarded the next ISTT Prize sponsored by genOway at the TT2011 meeting in Miami

30 September 2011: genOway: Financial results for the first half of 2011 (Only available in French)

7 September 2011: genOway obtains its first patent for its "KO - KI" technology (Only available in French)

5 September 2011: Implementation of liquidity contract with PORTZAMPARC Brokerage Company (Only available in French)

12 July 2011: genOway acquires worldwide exclusive license for RMCE technology from bluebird bio for genetically modified rodents

28 April 2011: genOway's customers fully satisfied with the company's offer and services (Dun & Bradstreet) (Only available in French)

31 March 2011: genOway annouces its financial results for 2010 (Only available in French)

20 January 2011: genOway commits against atherosclerosis and expands its range of products (Only available in French)

10 January 2011: Mr. Olivier Costa de Beauregard, Managing Director of the Dassault Group, has been nominated to genOway's Board of Directors

8 December 2010: genOway receives NYSE Euronext award from Deloitte Technology Fast 50 (Only available in French)

3 November 2010: genOway extends the exclusivity of its offer in pharmacology - toxicology (Only available in French)

1 October 2010: genOway: strong growth and increased profitability in the first half of 2010 (Only available in French)

20 September 2010: genOway announces General Service Agreements with Johann-Wolfgang-Goethe University Frankfurt (Only available in French)

6 September 2010: genOway: growth outlook reinforced by dynamic market (Only available in French)

7 July 2010: genOway: management strengthens its position in the capital of the Company (Only available in French)

14 June 2010: genOway improves its growth with major Japanese biopharmaceutical companies

8 June 2010: genOway : Edouard P. Croufer appointed to the Board of Directors

18 May 2010: genOway to present at the innovation week of the World Expo Shanghai 2010 (Only available in French)

17 May 2010: genOway and Griffith University sign promising research partnership and world wide exclusive license for olfactory stem cells technology

3 May 2010: genOway renewals 2.5 million Euros biopharmaceutical agreement (Only available in French)

19 April 2010: genOway, a strategic partner for European programs Myores and AtheroRemo (Only available in French)

7 April 2010: genOway renewals framework agreement of several million Euros with one of the world's leading biopharmaceutical companies (Only available in French)

31 March 2010: genOway annouces its financial results for 2009 (Only available in French)

18 February 2010: genOway and Cellectis close their disagreement

21 December 2009: genOway chosen by Tufts University for major framework contract

15 December 2009: genOway : 2 years renewable framework agreement with the University of Pittsburgh, 6th U.S. research center (Only available in French)

7 December 2009: genOway announces important Framework agreement with BIDMC, Harvard Medical School's Teaching Hospital

13 November 2009: genOway will appeal the decision of the TGI of November 12, 2009 (Only available in French)

4 November 2009: genOway announces important framework agreement with UPenn (University of Pennsylvania) one of the top ten U.S universities (Only available in French)

29 October 2009: genOway launches its "Knock-in 2in1" technology based on its proprietary "StemCell HY" platform.

20 October 2009: genOway acquires exclusive license for Flex technology developed by Professor Pierre Chambon and Dr. Norbert Ghyselinck at the IGBMC

30 September 2009: genOway annouces its half year results for 2009 (Only available in French)

10 September 2009: genOway's expertise selected as part of the AD-Inov consortium

2 September 2009: genOway: strong growth of academic customer portfolio in the first semester of 2009

14 May 2009: genOway reports the expansion of its business with major biopharmaceutical companies in first quarter of 2009

6 April 2009: genOway annouces its financial results for 2008 (Only available in french)

11 February 2009: genOway introduces StemCellHY, a new production technology

13 January 2009: genOway announces a 2-year general agreement with the renowned IMM - University of Zurich

06 January 2009: genOway launches a legal action against Cellectis S.A. and claims several millions euros for compensation

29 September 2008: genOway annouces its half year results for 2008 (Only available in French)

9 June 2008: Project IT- DIAB : genOway obtains € 1.1 million funding from OSEO and the exclusive distribution of the research models created

7 April 2008: genOway announces its financial results for 2007. (Only available in French)

2 April 2008: genOway signs a major master services agreement with the Japanese pharmaceuticals leader Eisai Co. Ltd.

25 March 2008: genOway: master service agreement with Boehringer Ingelheim Pharmaceuticals Inc.

19 November 2007 : genOway launches standardized genetically modified mousse and rat research models

17 October 2007 : genOway signs a contract for up to 2 Million USD in intended services with a US-based leading biopharmaceutical firm

19 September 2007: genOway annouces its half year results for 2007 (Only available in French)

May 2007: genOway is successfully entering the stock market: Capital raised will accelerate the transgenic company's technological innovation and industrialization process (Only available in French)

23 March 2007: genOway annouces its financial results for 2006 (Only available in French)

Annual reports / Registration Documents

Annual reports and registration documents are only available in French.

Shareholder's Documentation

Annual Shareholder's meeting, June 28, 2017
Documentation only available in French.

Annual Shareholder's meeting, May 31, 2016
Documentation only available in French.

Annual Shareholder's meeting, June 23, 2015
Documentation only available in French.

Annual Shareholder's meeting, September 18, 2014
Documentation only available in French.

Annual Shareholder's meeting, June 30, 2014
Documentation only available in French.

Annual Shareholder's meeting, June 3, 2013
Documentation only available in French.

Annual Shareholder's meeting, June 4, 2012
Documentation only available in French.

Annual Shareholder's meeting, June 7, 2011
Documentation only available in French.

Annual Shareholder's meeting, January 6, 2011
Documentation only available in French.

Annual Shareholder's meeting, June 7, 2010
Documentation only available in French.

Annual Shareholder's meeting, June 8, 2009
Documentation only available in French.

Annual Shareholder's Meeting, June 26, 2008
Documentation only available in French.